Eye Doctor and Fox News Regular Eyed as New Head of FDA Vaccine Division
FDA may pick Dr. Hemmati to lead CBER, which could speed up vaccine and biotech drug approvals, but decision is not final.
/ 1659 items
#XY↓
Activist Investors Bid $2.25 Per Share to Take Over SEER
Activist investors offer to buy Seer for $2.25/share cash + CVR, criticize CEO, and push board to respond by Apr 22.
Analysts Turn Bullish on Biohaven, Caris, and Veracyte
Canaccord says Biohaven is undervalued and could rise on epilepsy trial results. Jefferies likes Caris Life Sciences and Veracyte, citing strong growth in cancer diagnostics and solid finances.
TD Securities Sees Strong 2026 Growth for Tempus AI
TD Cowen upgraded Tempus AI to Buy, $65 target, citing strong growth in AI pharma tools despite recent stock drop.
Jhunjhunwala-Backed IKS in Advanced Talks to Buy Nasdaq’s TruBridge for $600M
IKS nearing $600M buy of TruBridge to boost US healthcare billing/RCM, expand AI-driven services and market share.
Pancreatic Cancer Breakthrough: New Daily Pill Nearly Doubles Survival in Major Trial
New drug daraxonrasib from Revolution Medicines doubled survival in pancreatic cancer (13.2 vs 6.7 months) and cut death risk by 60% in Phase 3.